{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:20:08Z","timestamp":1773213608864,"version":"3.50.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000026","name":"HHS | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U01 DA051658"],"award-info":[{"award-number":["U01 DA051658"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Fentanyl and other synthetic opioids are the leading cause of drug-related deaths in the United States. mAbs that selectively target fentanyl and fentanyl analogues offer a promising strategy for treating both opioid-related overdoses and opioid use disorders. To increase the duration of efficacy of a candidate mAb against fentanyl, we selected three sets of mutations in the Fc region of an IgG1 anti-fentanyl mAb (HY6-F9DF215, HY6-F9DHS, HY6-F9YTE) to increase binding to the neonatal Fc receptor (FcRn). The mAb mutants were compared against unmodified (wild-type [WT], HY6-F9WT) anti-fentanyl mAb for fentanyl binding, thermal stability, and FcRn affinity in vitro, and for efficacy against fentanyl and mAb half-life in vivo in mice. Biolayer interferometry showed a &amp;gt;10-fold increase in the affinity for recombinant FcRn of the three mutant mAbs compared with HY6-F9WT. During an acute fentanyl challenge in mice, all FcRn-mutated mAbs provided equal protection against fentanyl-induced effects, and all mAbs reduced brain fentanyl levels compared with the saline group. Serum persistence of the mutant mAbs was tested in Tg276 transgenic mice expressing human FcRn. After administration of 40 mg\/kg HY6-F9WT, HY6-F9DF215, HY6-F9DHS, and HY6-F9YTE, the mAbs showed half-lives of 6.3, 26.4, 14.7, and 6.9 d, respectively. These data suggest that modification of mAbs against fentanyl to bind to FcRn with higher affinity can increase their half-life relative to WT mAbs while maintaining efficacy against the toxic effects of fentanyl, further supporting their potential role as a therapeutic treatment option for opioid use disorder and overdose.<\/jats:p>","DOI":"10.4049\/jimmunol.2400170","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T19:26:34Z","timestamp":1721244394000},"page":"663-668","source":"Crossref","is-referenced-by-count":7,"title":["Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity"],"prefix":"10.1093","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2588-0900","authenticated-orcid":false,"given":"Aaron","family":"Khaimraj","sequence":"first","affiliation":[{"name":"Department of Pharmacology, University of Minnesota , Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-6776","authenticated-orcid":false,"given":"Carly A","family":"Baehr","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Minnesota , Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6934-4050","authenticated-orcid":false,"given":"Dustin","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Minnesota , Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D","family":"Raleigh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Minnesota , Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1036-0184","authenticated-orcid":false,"given":"Marco","family":"Pravetoni","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Washington , Seattle, WA"},{"name":"University of Washington Center for Medication Development for Substance Use Disorders, Garvey Institute for Brain Solutions , Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"2025012305144956000_r1","article-title":"Results from the 2020 national survey on drug use and health: detailed tables","author":"Center for Behavioral Health Statistics and Quality","year":"2021"},{"key":"2025012305144956000_r2","first-page":"1485","article-title":"Death rates for drug overdose among persons aged 25\u201344 Years, by race and ethnicity\u2014 United States, 2000\u20132020","volume-title":"MMWR Morb. Mortal. Wkly. Rep.","author":"CDC.","year":"2022"},{"key":"2025012305144956000_r3","article-title":"Drug overdose deaths in the United States, 2001\u20132021. NCHS Data Brief, no. 457","author":"Spencer","year":"2022"},{"key":"2025012305144956000_r4","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/pds.3901","article-title":"Prescription opioids, abuse and public health in Canada: Is fentanyl the new centre of the opioid crisis?","volume":"24","author":"Fischer","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"2025012305144956000_r5","first-page":"39","article-title":"Outcomes of opioid-dependence treatment across Europe: Identifying opportunities for improvement","volume":"14","author":"St\u00f6ver","year":"2012","journal-title":"Heroin Addict. Relat. Clin. Probl."},{"key":"2025012305144956000_r6","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2147\/PPA.S180641","article-title":"Current and future options for opioid use disorder: A survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine","volume":"12","author":"Gilman","year":"2018","journal-title":"Patient Prefer. Adherence"},{"key":"2025012305144956000_r7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","article-title":"A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction","volume":"30","author":"Veilleux","year":"2010","journal-title":"Clin. Psychol. Rev."},{"key":"2025012305144956000_r8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/JAN.0000000000000381","article-title":"Factors associated with relapse in individuals with opioid use disorder receiving suboxone in rural areas","volume":"32","author":"Chang","year":"2021","journal-title":"J. Addict. Nurs."},{"key":"2025012305144956000_r9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1046\/j.1360-0443.1996.911014797.x","article-title":"After antagonization of acute opiate overdose: A survey at hospitals in Vienna","volume":"91","author":"Seidler","year":"1996","journal-title":"Addiction"},{"key":"2025012305144956000_r10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drugalcdep.2016.02.024","article-title":"Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs","volume":"162","author":"Caudarella","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"2025012305144956000_r11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0736-4679(98)00019-5","article-title":"Nalmefene: A long-acting opioid antagonist","volume":"16","author":"Wang","year":"1998","journal-title":"J. Emerg. Med."},{"key":"2025012305144956000_r12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12954-022-00627-3","article-title":"Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders","volume":"19","author":"Abdelal","year":"2022","journal-title":"Harm. Reduct. J."},{"key":"2025012305144956000_r13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/10903127.2017.1315203","article-title":"Multiple naloxone administrations among emergency medical service providers is increasing","volume":"21","author":"Faul","year":"2017","journal-title":"Prehosp. Emerg. Care"},{"key":"2025012305144956000_r14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13011-019-0195-4","article-title":"Higher doses of naloxone are needed in the synthetic opiod era","volume":"14","author":"Moss","year":"2019","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"2025012305144956000_r15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13643-019-1048-y","article-title":"Naloxone interventions in opioid overdoses: A systematic review protocol","volume":"8","author":"Shaw","year":"2019","journal-title":"Syst. Rev."},{"key":"2025012305144956000_r16","doi-asserted-by":"crossref","first-page":"107662","DOI":"10.1016\/j.neuropharm.2019.06.001","article-title":"Development of vaccines to treat opioid use disorders and reduce incidence of overdose","volume":"158","author":"Pravetoni","year":"2019","journal-title":"Neuropharmacology"},{"key":"2025012305144956000_r17","doi-asserted-by":"crossref","first-page":"10489","DOI":"10.1021\/jacs.9b04872","article-title":"Monoclonal antibodies for combating synthetic opioid intoxication","volume":"141","author":"Smith","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"2025012305144956000_r18","doi-asserted-by":"crossref","first-page":"1991552","DOI":"10.1080\/19420862.2021.1991552","article-title":"Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice","volume":"13","author":"Ban","year":"2021","journal-title":"MAbs."},{"key":"2025012305144956000_r19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.120.000124","article-title":"Monoclonal antibodies counteract opioid-induced behavioral and toxic effects in mice and rats","volume":"375","author":"Baehr","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2025012305144956000_r20","doi-asserted-by":"crossref","first-page":"2122507","DOI":"10.1080\/21645515.2022.2122507","article-title":"Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development","volume":"18","author":"Hicks","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"2025012305144956000_r21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.121.001048","article-title":"Pharmacological profiling of antifentanyl monoclonal antibodies in combination with naloxone in pre- and postexposure models of fentanyl toxicity","volume":"381","author":"Baehr","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2025012305144956000_r22","doi-asserted-by":"crossref","first-page":"7700","DOI":"10.1038\/s41467-023-43126-0","article-title":"Investigation of monoclonal antibody CSX-1004 for fentanyl overdose","volume":"14","author":"Bremer","year":"2023","journal-title":"Nat. Commun."},{"key":"2025012305144956000_r23","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: The architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"key":"2025012305144956000_r24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.18.1.739","article-title":"Multiple roles for the major histocompatibility complex class I-related receptor FcRn","volume":"18","author":"Ghetie","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"2025012305144956000_r25","doi-asserted-by":"crossref","first-page":"9604","DOI":"10.3390\/ijms23179604","article-title":"Monoclonal antibody engineering and design to modulate FcRn activities: A comprehensive review","volume":"23","author":"Ramdani","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"2025012305144956000_r26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4049\/jimmunol.2100204","article-title":"Contribution of antibody-mediated effector functions to the mechanism of efficacy of vaccines for opioid use disorders","volume":"207","author":"Huseby Kelcher","year":"2021","journal-title":"J. Immunol."},{"key":"2025012305144956000_r27","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1038\/s41467-019-13108-2","article-title":"An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"2025012305144956000_r28","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc Receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2025012305144956000_r29","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences","volume":"169","author":"Dall'Acqua","year":"2002","journal-title":"J. Immunol."},{"key":"2025012305144956000_r30","first-page":"1098","article-title":"Extending human IgG half-life using structure-guided design","volume":"10","author":"Booth","year":"2018","journal-title":"MAbs."},{"key":"2025012305144956000_r31","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/intimm\/dxl110","article-title":"Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease","volume":"18","author":"Petkova","year":"2006","journal-title":"Int. Immunol."},{"key":"2025012305144956000_r32","doi-asserted-by":"crossref","first-page":"14647","DOI":"10.1021\/acs.jmedchem.0c01042","article-title":"Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity","volume":"63","author":"Robinson","year":"2020","journal-title":"J. Med. Chem."},{"key":"2025012305144956000_r33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.112.201194","article-title":"Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats","volume":"344","author":"Raleigh","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2025012305144956000_r34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"key":"2025012305144956000_r35","doi-asserted-by":"crossref","first-page":"1366186","DOI":"10.3389\/fpsyt.2024.1366186","article-title":"Evaluating the rate of reversal of fentanyl-induced respiratory depression using a novel long-acting naloxone nanoparticle, cNLX-NP","volume":"15","author":"Averick","year":"2024","journal-title":"Front. Psychiatry"},{"key":"2025012305144956000_r36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","article-title":"Non-compartmental analysis","volume":"929","author":"Gabrielsson","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"2025012305144956000_r37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","article-title":"Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering","volume":"35","author":"Ko","year":"2021","journal-title":"BioDrugs"},{"key":"2025012305144956000_r38","doi-asserted-by":"crossref","first-page":"E230023","DOI":"10.1001\/jamanetworkopen.2023.0023","article-title":"Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: A systematic review and network meta-analysis","volume":"6","author":"Sun","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"2025012305144956000_r39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41541-021-00329-0","article-title":"Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge","volume":"6","author":"Stone","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2025012305144956000_r40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41541-020-00247-7","article-title":"Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders","volume":"5","author":"Crouse","year":"2020","journal-title":"NPJ Vaccines"},{"key":"2025012305144956000_r41","doi-asserted-by":"crossref","first-page":"112049","DOI":"10.1016\/j.celrep.2023.112049","article-title":"A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl","volume":"42","author":"Triller","year":"2023","journal-title":"Cell Rep."},{"key":"2025012305144956000_r42","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int. Immunol."},{"key":"2025012305144956000_r43","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI106279","article-title":"Metabolic properties of IgG subclasses in man","volume":"49","author":"Morell","year":"1970","journal-title":"J. Clin. Invest."},{"key":"2025012305144956000_r44","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/19420862.2016.1193660","article-title":"Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies","volume":"8","author":"Avery","year":"2016","journal-title":"MAbs"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/213\/5\/663\/61262443\/ji2400170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/213\/5\/663\/61262443\/ji2400170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:16:25Z","timestamp":1737609385000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/213\/5\/663\/7921649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.2400170","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,17]]}}}